AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.
about
A deficiency in CCR2+ monocytes: the hidden side of Alzheimer's diseaseThe anti-aging effects of LW-AFC via correcting immune dysfunctions in senescence accelerated mouse resistant 1 (SAMR1) strainCCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease.CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic miceAmyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammationIsoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal modelThe classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain.FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disordersAltered hippocampal synaptic transmission in transgenic mice with astrocyte-targeted enhanced CCL2 expression.Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infectionThe anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease.Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain.FOXO3a inhibits TNF-α- and IL-1β-induced astrocyte proliferation:Implication for reactive astrogliosisBeta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer's disease mice.Microglia and inflammation in Alzheimer's disease.Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice.Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease.Spatial Learning Requires mGlu5 Signalling in the Dorsal Hippocampus.Effects of neural stem cells on synaptic proteins and memory in a mouse model of Alzheimer's disease.Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of Alzheimer disease.Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer's disease.URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice.Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?
P2860
Q26997058-7F1759BC-418B-4FBA-9119-C3F728C5B95FQ30819335-8A4E4AAF-E4EC-488D-BD9B-E35A7F31A2F6Q33572146-7C626226-1A47-4F0F-8522-98C05A34EA57Q34017180-00AAC184-92D8-45C9-BAD2-81C767E0DDBEQ34227162-CF2DDEFD-0F79-45EE-8C9D-6C5DB4045D87Q35025065-0A6C0DE8-5F6E-42F9-95D7-D592A2F16F1FQ35197124-5CDB4F31-E5F6-4072-AA03-58417AA0EFCCQ35570991-D7529D85-D667-47E6-9524-8B3CAF4620AEQ35599843-1ECA9CC1-DC18-4B5C-BDFE-1D8BDB57C491Q35621081-E21384E8-7258-4506-9C44-1C9E511F7BEBQ35743736-CF0E24F5-A869-4822-B754-2A61C80B297EQ36607168-7C1BB4C1-88DC-47E3-AC97-96D7EAD917F4Q36635842-AFA0E6E2-9660-4CD4-8847-BCF42E7E5596Q37053459-80518C29-2E7B-45AA-8DE6-19E216CF762EQ37106118-39779FB0-5EF8-44BC-9D2D-4135814B488FQ37425227-0122421B-B66B-4503-8788-5295FA359255Q37703295-068DAED7-08CA-4660-9F07-C7AB0CAF60E9Q38761724-806DB966-D8ED-4A51-8F9A-26EAFB9F883BQ38856794-15988875-C97B-4CCB-A9A0-C54B45F9A628Q39136603-C69536F3-0ADB-4A00-B934-1B5355890FE0Q39893541-A619C800-4C5F-4B09-8155-28E628ADEC67Q40410864-2078B19C-B5E3-405C-94DB-82F758936D6BQ41750798-393E2F6A-B64A-49BA-9DB0-8D40F3C98753Q44763772-01E03FDB-5888-4649-BA67-7C231380F66FQ47137633-7D9893BD-5106-4077-8A42-B4CFFCEB2BC3Q47980519-AB8AC620-A449-414F-8734-793548118847Q50692044-4C2D52C3-0D58-4A97-8FCB-EA3A213E2870Q54979695-02B08618-C151-4673-A508-2050366B5A96Q55380454-FE274A22-F0A7-4014-A449-64C183BE172EQ58727052-6730E5A5-9CA1-4B55-828F-90EC969482F2
P2860
AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@en
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@nl
type
label
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@en
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@nl
prefLabel
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@en
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@nl
P2093
P2860
P356
P1433
P1476
AAV1/2-mediated CNS gene deliv ...... ng impairment of APP/PS1 mice.
@en
P2093
Bryce Schroder
Howard E Gendelman
Mary P Lambert
Masaru Yamamoto
Michael T Jacobsen
Richard M Ransohoff
Russell J Swan
Tomomi Kiyota
Tsuneya Ikezu
William L Klein
P2860
P304
P356
10.1038/MT.2009.44
P577
2009-03-10T00:00:00Z